There are 2934 resources available
5130 - OCTOPUS - A Randomised, Multi-centre Phase II Umbrella Trial of Weekly Paclitaxel+/- Novel Agents in Platinum-Resistant Ovarian Cancer: vistusertib
Presenter: Susana Banerjee
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
1638 - Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study
Presenter: Fabrice Barlesi
Session: Proffered Paper – CNS tumours
Resources:
Abstract
Slides
Webcast
4648 - Prognostic role of the EANO ESMO classification of leptomeningeal metastases
Presenter: Emilie Le Rhun
Session: Proffered Paper – CNS tumours
Resources:
Abstract
Slides
4361 - A Phase 0/2 Clinical Trial of a CDK4/6 Inhibitor in Aggressive Meningioma Patients
Presenter: Nader Sanai
Session: Proffered Paper – CNS tumours
Resources:
Abstract
Slides
Webcast
1688 - Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients
Presenter: Mario Caccese
Session: Proffered Paper – CNS tumours
Resources:
Abstract
Slides
Webcast
4884 - Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain
Presenter: Laura Chow
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
2693 - Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases
Presenter: Yanjun Xu
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
2560 - BAROCCO: A randomized phase II study of weekly paclitaxel vs. cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)
Presenter: Nicoletta Colombo
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
6602 - Phase 1B/2 Study of AVB500 (High Affinity Inhibitor of GAS6/AXL Path) in Combination with PAC and PLD in Platinum Resistant Recurrent Ovarian Cancer
Presenter: Bradley Monk
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
1547 - Randomized Phase 2 (RP2) Study of ATR inhibitor M6620 in Combination with Gemcitabine versus Gemcitabine alone in Platinum-Resistant High Grade Serous Ovarian Cancer (HGSOC)
Presenter: Panagiotis Konstantinopoulos
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast